RLMD - NASDAQ
Relmada Therapeutics, Inc.
$6.38
-0.62%Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
At a Glance
Live SnapshotNo Revenue Data
RLMD has not reported any revenue values in the available annual periods.
Relmada Therapeutics, Inc. Profit Bridge
Profitability Analysis
Relmada Therapeutics, Inc. Income Statement
RLMD • NASDAQ
| Relmada Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Aug 2013 | Aug 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.1K | 7.9K | |
GROSS PROFIT | ||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (4.9K) | (2.6K) | (85.3K) | (54.8K) | (9.3K) | (4K) | (5.8K) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -4.9K | -2.6K | -85.3K | -54.8K | -9.3K | 1.1K | 2.1K | |
OPERATING INCOME | ||||||||||||||
(59.1M) | (83.9M) | (103.7M) | (161.2M) | (125.7M) | (60.8M) | (15.1M) | (12.7M) | (6.9M) | (7.2M) | (16.2M) | (17.1M) | (46.1K) | (14.2K) | |
(311.9K) | (37.7M) | (48.9M) | (47.9M) | (35.1M) | (24.9M) | (7.3M) | (5.7M) | (4M) | (5.7M) | (9.9M) | (9.2M) | (46.1K) | (13.8K) | |
(744.6K) | (46.2M) | (54.8M) | (113.3M) | (90.6M) | (36M) | (7.9M) | (7M) | (2.9M) | (1.3M) | (6.2M) | (7.9M) | (0.0) | (0.0) | |
-59.1M | -83.9M | -103.7M | -161.2M | -125.7M | -60.8M | -15.1M | -12.7M | -6.9M | -7.2M | -16.2M | -17.1M | -45K | -12.1K | |
PRE-TAX INCOME | ||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (1.3M) | (550.0) | (0.0) | (4.9K) | (0.0) | (0.0) | |
1.4M | 3.5M | 5.2M | 2.7M | 1.2M | 1.4M | 0.0 | 0.0 | -1.3M | -550.0 | 0.0 | 6K | 0.0 | 0.0 | |
(58M) | (0.0) | (0.0) | (923.0) | (0.0) | (0.0) | (0.0) | (0.0) | (2.4K) | (0.0) | (130.3K) | (0.0) | (0.0) | (0.0) | |
1.7M | 3.9M | 4.9M | 4.2M | -48.3K | 1.4M | 104.1K | -5.7M | -2M | 932.3K | 13.2M | -3.7M | 0.0 | 0.0 | |
-57.4M | -80M | -98.8M | -157M | -125.8M | -59.5M | -15M | -17.3M | -9M | -6.3M | -3M | -20.8M | -45K | -12.1K | |
NET INCOME | ||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (4.6M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-57.4M | -80M | -98.8M | -157M | -125.8M | -59.5M | -15M | -17.3M | -9M | -6.3M | -3M | -20.8M | -45K | -12.1K |
SEC Filings
RLMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 28, 2026 | May 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | May 27, 2026 | 2026 | |
S-3 S-3 N/A | April 03, 2026 | April 03, 2026 | ||
8-K 8-K 2026 N/A | March 20, 2026 | March 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 15, 2025 | December 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 |
Related Guides
Continue your RLMD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.